Intellia director granted RSUs and options
Intellia Therapeutics director Georgia Keresty received equity compensation in the form of restricted stock units and stock options.
Rhea-AI Filing Summary
Intellia Therapeutics director Georgia Keresty received equity compensation in the form of restricted stock units and stock options. She acquired 9,200 shares of common stock at no cost through a grant of restricted stock units, bringing her direct holdings to 41,083 shares.
Keresty was also granted stock options covering 13,300 shares of common stock at an exercise price of $12.89 per share. According to the terms, this option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders following the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 22,500 shares
Grant/Award
2 txns
Insider
Keresty Georgia
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 13,300 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 9,200 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 13,300 contracts (Direct);
Common Stock — 41,083 shares (Direct)
Footnotes (2)
- F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- F2. This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Key Figures
RSU shares granted: 9,200 shares
Options granted: 13,300 shares
Option exercise price: $12.89 per share
+2 more
5 metrics
RSU shares granted
9,200 shares
Restricted stock unit grant of common stock on June 9, 2026
Options granted
13,300 shares
Stock Option (right to buy) granted on June 9, 2026
Option exercise price
$12.89 per share
Exercise price for 13,300-share stock option grant
Shares held after grant
41,083 shares
Total common shares directly held by Keresty after RSU award
Option expiration date
June 8, 2036
Expiration of 13,300-share stock option grant
Key Terms
restricted stock units, Stock Option (right to buy), exercise price, vests in full, +1 more
5 terms
restricted stock units financial
"Based on a grant of restricted stock units representing a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"Stock Option (right to buy) with respect to 13,300 shares of Common Stock"
exercise price financial
"conversion or exercise price of 12.8900 for the stock option grant"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in full financial
"This option was granted ... and vests in full on the earlier to occur"
annual meeting of stockholders financial
"or (b) the date of the next annual meeting of stockholders following the date of grant"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Intellia Therapeutics (NTLA) director Georgia Keresty acquire in this Form 4?
Georgia Keresty received equity compensation consisting of 9,200 shares of Intellia Therapeutics common stock via restricted stock units and stock options for 13,300 shares. These awards are grants, not open-market purchases, and increase her direct equity exposure to the company.
What are the key terms of Georgia Keresty’s Intellia Therapeutics stock option grant?
Keresty received stock options for 13,300 shares of Intellia common stock with an exercise price of $12.89 per share. The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the next annual meeting of stockholders.
Are Georgia Keresty’s Intellia Therapeutics (NTLA) transactions open-market buys or compensation grants?
The transactions are compensation-related grants, not open-market purchases. The Form 4 lists transaction code “A” for awards of 9,200 restricted stock units and 13,300 stock options, both described as grant or award acquisitions provided at no cash cost per share on the transaction date.
How do the restricted stock units reported for Intellia Therapeutics (NTLA) work?
The filing states the 9,200-share award is a grant of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The units convert into actual shares only upon vesting, aligning director compensation with long-term shareholder interests.
When will Georgia Keresty’s Intellia Therapeutics stock options fully vest?
The stock options granted on June 9, 2026 vest in full on the earlier of two dates: the first anniversary of the grant date or the date of the next annual meeting of stockholders after the grant. This provides a clear, time-based vesting schedule for the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
